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Abstract
Background: The Phosphatidylinositol 39-kinase is a key regulator in various cancer-associated signal transduction
pathways. Genetic alterations of its catalytic subunit alpha, PIK3CA, have been identified in ovarian cancer. Our in vivo data
suggests that PIK3CA activation is one of the early genetic events in ovarian cancer. However, its role in malignant
transformation of ovarian surface epithelium (OSE) is largely unclear.
Methodology/Principal Findings: Using the Mu ¨llerian inhibiting substance type II receptor (MISIIR) promoter, we generated
transgenic mice that expressed activated PIK3CA in the Mu ¨llerian epithelium. Overexpression of PIK3CA in OSE induced
remarkable hyperplasia, but was not able to malignantly transform OSE in vivo. The consistent result was also observed in
primary cultured OSEs. Although enforced expression of PIK3CA could not induce OSE anchorage-independent growth, it
significantly increased anchorage-independent growth of OSE transformed by mutant K-ras.
Conclusions/Significance: While PIK3CA activation may not be able to initiate OSE transformation, we conclude that
activation of PIK3CA may be an important molecular event contributing to the maintenance of OSE transformation initiated
by oncogenes such as K-ras.
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Introduction
Epithelial ovarian cancer continues to be the leading cause of
death among gynecological malignancies [1,2,3]. The lack of
effective methods for prevention, early detection and treatment
recurrent ovarian tumors creates a pressing need to understand its
pathogenesis and identify molecular targets for therapy. Cancer is
a disease involving multistep dynamic changes in the genome [4].
However, the oncogenic events and their cooperation that
promote malignant transformation in ovarian carcinoma remain
largely unknown [2,3,5,6,7,8,9,10].
Phosphatidylinositol-39kinase (PI-3 kinase) is an intracellular signal
transducer with lipid substrate specificity implicated in a wide range
of cancer-associated signaling pathways including tumor cell meta-
bolism, survival and proliferation [11,12,13,14,15,16,17,18,19]. It is
recruited and activated by multiple receptor tyrosine kinases and
generates second messengers via phosphorylation of membrane
inositol lipids at the D3 position [11,12,13,14]. PI-3 kinase was first
recognized as a putative oncogene because of its ability to bind
polyoma middle T antigen [20,21]. Molecular cloning of PI-3 kinases
revealed a large and complex family that contains three classes with
multiple subunits and isoforms [11,12,13,14]. The PIK3CA gene
encodes the catalytic subunit p110-alpha, one of the three catalytic
subunit proteins of the class IA PI-3 kinases [11,12,13,14].
PIK3CA was identified as an avian retrovirus-encoded oncogene that
can transform chicken embryo fibroblasts [22]. Numerous recent
studies indicate that PIK3CA and downstream pathways are
frequently targeted by genomic amplification [23], mutation [24]
or overexpression [25] in solid tumors including ovarian cancer
[23,25,26,27,28,29,30,31,32]. Previous studies on the function of
PIK3CA in ovarian cancers have been predominantly focused on
the maintenance and survival of late-stage of ovarian carcinoma. The
function of PIK3CA in malignant transformation of the ovarian
surface epithelium (OSE) remains unexplored. Here we
generated transgenic mice expressing constitutively activated (myr-
istoilated) PIK3CA in the Mu ¨llerian epithelium of the female
genital tract to investigate the effect of PIK3CA overexpression in
the OSE.
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PIK3CA overexpression was an early genetic event during
ovarian tumorigenesis
In many human tumors, including epithelial ovarian cancer
[23,25,26,27,28,29,30], PIK3CA activation is a critical oncogenic
event and can be mediated by multiple genetic/genomic
alterations such as gene copy number amplification [23], gain of
functional mutations [24], and transcriptional up-regulation
[33,34,35]. However, the function of PIK3CA activation during
the process of malignant transformation of OSE is still not well
understood. Our previous studies indicate that mRNA expression
of PIK3CA is significantly up-regulated in the early-stage of ovarian
cancer development, strongly suggesting that PIK3CA might be
involved in OSE transformation [25]. To confirm our previous
finding, we first compared expression levels of PIK3CA mRNA in
established epithelial ovarian cancer cell lines (n=15) with
primary cultures of immortalized human ovarian surface epithe-
liums (IOSEs, n=6). Consistently, we found that mRNA levels in
epithelial tumor cell lines were significantly higher than in IOSEs
(p=0.041, Figure 1A). Next, we examined mRNA expression of
PIK3CA in microdissected normal human ovarian epithelium
(n=4) as well as epithelial ovarian cancer specimens including
FIGO stages I (n=16), II (n=8), III (n=31) and IV (n=11). We
found that mRNA expression level of PIK3CA was significantly
upregulated in ovarian cancer specimens compared to normal
control ovarian epithelium (p,0.02), and there was no further
significant increase after malignant transformation among differ-
ent stages of ovarian cancer (p.0.05, Figure 1B), which is
consistent with our previous observation [25]. To further confirm
PIK3CA is indeed expressed in early-stage ovarian cancer, we also
examined the protein product of PIK3CA gene, p110a,b y
immunohistochemical staining in early malignant transformed
human ovarian surface epithelium. We found that p110a was
highly detectable in the early malignant transformed human
ovarian surface epithelium (Figure 2A and B). Taken together,
Figure 1. PIK3CA overexpression was an early genetic event during ovarian tumorigenesis. A. PIK3CA mRNA expression was significantly
up-regulated in the established epithelial ovarian cancer cell lines (n=15) compared with primary cultured ovarian surface epithelial cells (n=6,
p=0.041). mRNA expression was measured by real-time RT-PCR. B. mRNA expression level of PIK3CA was significantly upregulated in ovarian cancer
specimens compared with normal control ovarian epithelium. Normal ovarian epithelium was isolated by laser-capture microdissection. There was no
further significant increase of PIK3CA mRNA expression after malignant transformation among different stages of ovarian cancer.
doi:10.1371/journal.pone.0004295.g001
Figure 2. High p110a expression was detected in early malignant transformed human ovarian surface epithelium. p110a expression
was detected by immunohistochemical staining. A. High p110a expression was detected in early malignant transformed human ovarian surface
epithelium (100X). B. High magnification of A (400X).
doi:10.1371/journal.pone.0004295.g002
PIK3CA in OSE Transformation
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genetic event during ovarian oncogenesis, thus suggesting that
PIK3CA activation might be causally involved in this process.
Generation of transgenic mice expressing activated
PIK3CA in the Mu ¨llerian epithelium
To investigate the role of PIK3CA in malignant transformation
of the OSE in vivo, we generated transgenic mice in which
activated PIK3CA was specifically overexpressed in the Mu ¨llerian
epithelium of the female reproductive tract including OSE. In this
model, we used the Mu ¨llerian epithelium specific promoter,
Mu ¨llerian inhibiting substance type II receptor promoter (MISIIR)
[36,37,38,39], to drive expression of the murine PIK3CA (Figure 3).
In the male animal, Mu ¨llerian inhibiting substance (MIS)i s
secreted from Sertoli cells of the developing testes and stimulates
the regression of the Mullerian duct. Testosterone is also secreted
from the developing testes and induces the differentiation of the
Wolffian duct into the secondary structures of the male
reproductive tract. In the absence of MIS in the developing
female embryo, the Mullerian duct differentiates into the
secondary structures of the female reproductive tract
[36,37,38,39]. Expression of the MISIIR has been reported to be
restricted to mesenchymal cells surrounding the Mullerian duct
during embryogenesis, tubular and follicular structures of fetal
gonads, Sertoli and Leydig cells of adult testis, and granulosa cells
of adult ovary [36,37,38,39]. Above information provides a
possible strategy to develop a transgenic model of ovarian
carcinoma [39]. Using this promoter, Connolly et al. have
successfully developed the very first ovarian cancer transgenic
models that develop ovarian carcinomas with metastatic spread to
peritoneal organs [39]. In addition, increasing evidence indicates
that PIK3CA is activated in a large percentage of human ovarian
cancer patients [25,27,35]. Therefore, we generated the activating
mutation by addition of the avian src myristoylation sequence
(MGSSKSKPK) at the N-terminus of the wild type of murine
PIK3CA to constitutively activate PI3-kinase pathway in vivo.T o
demonstrate that our transgenic construct was able to constitu-
tively activate PI3-kinase pathway, we transient transfected myr-
PIK3CA, wt-PIK3CA and control vectors to ovarian cancer cell line
2008. 48 hrs of post-transfection, the transfected cells were
cultured in low serum overnight. Protein and total RNA were
isolated from cells. Real-time RT-PCR demonstrated that cells
from wt-PIK3CA and myr-PIK3CA transfections were expressed
similar levels of PIK3CA mRNA, which was about 11.5-fold higher
comparing to cells from control vector transfection. Total and
phosphate AKT, the downstream molecule of PI3-kinase pathway,
were examined by western blot. Figure 4 showed that myr-PIK3CA
was able to constitutively activate AKT in low serum condition
(1%) compared with wt-PIK3CA and control transfection.
Twelve founder lines of MISIIR-PIK3CA transgenic (PIK3CA-
Tg) mice were generated, in which the genomic integration of
whole MISIIRpr-myrPIK3CA-IRES-GFP sequence was confirmed
by two sets of genotyping primers (Figure 5A). Expression of the
transgene mRNA (eGFP) was examined by RT-PCR in the
samples from the female whole ovary of the genotype-positive
mice. In three of the transgenic lines, the eGFP mRNA transcript
was able to be detected in vivo (Figure 5B). Three founder PIK3CA-
Tg lines (#6, #22 and #26), three control lines (genotype positive,
eGFP mRNA negative #3, #12 and #44, Figure 5B) and wild
type mice (genotype negative mice) were used for further studies.
Overexpression of activated PIK3CA in OSE resulted in
hyperplasia but not tumor formation
To confirm overexpression of PIK3CA in the OSEs of transgenic
mouse, we microdissected the OSE cells from PIK3CA-Tg and WT
mice using laser capture microdissetion (LCM, Figure 6A). Total
RNA was isolated, and PIK3CA mRNA expression was measured
by real-time RT-PCR. We found that PIK3CA mRNA expression
level was 18.5-fold higher in OSEs from PIK3CA-Tg mice (200.93
689.47 relative expression unit) than from WT mice (10.87 6
7.28 relative expression unit, p=0.009, Figure 6B). In addition, by
immunohistochemistry (using two different antibodies), we con-
firmed that p110a was highly expressed in the OSE of the
PIK3CA-Tg mice (data not shown). Then, we followed up the
ovarian tumor development in PIK3CA-Tg mice. We found that
expression of the activated PIK3CA resulted in hyperplasia in
mouse OSE and a paucity of follicles in four month-old female
mice. Female transgenic PIK3CA-Tg mice exhibited subfertility.
Figure 7A shows the typical OSE in 5-month control female mice.
The Cytokeratin (an epithelial marker) positive OSE was observed
Figure 3. The illustration of the construct that was used to generate transgenic mouse. The arrows show two sets of the genotyping
primers and one set of the RT-PCR primers.
doi:10.1371/journal.pone.0004295.g003
Figure 4. myr-PKI3CA was able to active PI3-kinase pathway.
myr-PIK3CA, wt-PIK3CA and control vectors were transient transfected
to ovarian cancer cell line 2008. 48 hrs of post-transfection, transfected
cells were cultured in 1% serum over night. Total and phosphate AKT
were detected by western blot.
doi:10.1371/journal.pone.0004295.g004
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hyperplasia was found in the OSE, and the epithelial origin of the
lesions was confirmed by Cytokeratin staining (Figure 7B).
Hyperplasia was found in more than 50% of the PIK3CA-Tg
mice after four months post-birth, and in 100% of the PIK3CA-Tg
mice after ten months post-birth. There were no invaginations or
papillary structures observed in the OSE of PIK3CA-Tg mice. In
the control mice, no significant hyperplasia in OSE was observed
even after 12 months of post-birth. These results suggest that
expression of activated PIK3CA in OSE induced hyperplasia of the
OSE. We monitored for ovarian tumor development in both the
transgenic and control mouse lines. A total of 218 female PIK3CA-
Tg mice (#6: n=94; #22: n=44 and #26: n=80) were
evaluated (at least 30 mice of each line were followed for more
than 18 months) and no epithelial ovarian tumors were observed.
There was no difference in life span between the transgenic mice
Figure 5. Generation of transgenic mice expressing activated PIK3CA in the Mu ¨llerian epithelium. A. A total of 12 founder lines were
generated. Upper panel shows the genotyping by PCR using the first set of the genotyping primers. Lower panel shows the genotyping by PCR using
the second set of the genotyping primers. B. The transgene (eGFP) was able to be detected in 3 founder lines by RT-PCR.
doi:10.1371/journal.pone.0004295.g005
Figure 6. PIK3CA was overexpressed in OSE of PIK3CA-Tg mouse. A. Ovarian surface epithelial cells were microdissected by laser capture
microdissection technology. B. PIK3CA mRNA expression in OSEs from WT or PIK3CA-Tg OSEs was analyzed by real-time RT-PCR. The primers were
able to detected both wt PIK3CA cDNA and cDNA from transgene expression (myr-PIK3CA).
doi:10.1371/journal.pone.0004295.g006
PIK3CA in OSE Transformation
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activated PIK3CA in OSE causes hyperplasia in vivo but not tumor
formation.
PIK3CA contributed to K-ras initiated transformation in
vitro
To further confirm the above in vivo observation, we next tested
the role of PIK3CA in OSE transformation in vitro. Primary murine
OSE cells (MOSEs) were isolated from ovaries of female mice and
cultured short-term (only early passage, ,10 passages, cells were
used in this study) [40]. Soft agar assay was used to evaluate the
potential contribution of PIK3CA in transformation of OSE [41].
Because PI3-kinase/PTEN-ras [8] and PI3-kinase/AKT-myc [5]
pathways have been reported involving in OSE transformation, we
chose ras and c-myc in our following studies. Myr-PIK3CA
(pUSEamp-myr-mPIK3CA, under CMV promoter, G418), K-
ras
v12 and c-myc (both in pBabe-puro vector, puromycin)
expression vectors were transfected to MOSE cells. The pooled
stable expression cells were generated by short-term antibiotic
selection (10 days for G418 or 3 days for puromycin). The
transgene expression was further confirmed by RT-PCR. We
found that overexpression of PIK3CA alone did not significantly
increase anchorage-independent growth of OSEs (Figure 8A). In
contrast, introduce of either mutant K-ras of c-myc resulted in
increased colony formation of OSEs (Figure 8A). This result
indicates that unlike mutant K-ras or c-myc, PIK3CA is not able to
cause complete transformation of OSE in vitro. Next, we tested the
combination of PIK3CA with either of the two other oncogenes by
co-transfection. The myr-PIK3CA was transfected first. After
10 days G418 selection, K-ras or c-myc was transfected subsequent-
ly and selected again by puromycin for 3 days. Interestingly, we
found that combining PIK3CA and mutant K-ras significantly
increased anchorage-independent growth of cultured OSE cells
compared with mutant K-ras alone (Figure 8A). However, PIK3CA
did not significantly increase colony numbers of OSE cells
transformed by c-myc (Figure 8A). This finding suggests that early
activation of PIK3CA might promote transformation of OSE cells
in certain cellular and molecular contexts, e.g. in the presence of
K-ras mutation. To further confirm that PIK3CA can play a role in
transformation induced by mutant K-ras, we blocked endogenous
PIK3CA expression in cultured OSE cells transfected with mutant
K-ras by RNA interference using small interfering RNAs (siRNA).
The efficiency of the siRNA targeting mPIK3CA was confirmed by
real-time RT-PCR (mRNA expression of mPIK3CA was knocked
down to ,30% in the siRNA treated cells compared with control
cells, data not shown). The specificity of the siRNA was also
examined by measuring endogenous mPIK3CB expression (there
was no significantly difference of PIK3CB mRNA expression
between siRNA treated and control cells, data not shown). We
found that in the absence of PIK3CA, the transformed OSEs could
not grow in soft agar (Figure 8B), which suggests that the growth of
K-ras transfected OSE cells require PIK3CA expression. However,
it is still unclear whether PIK3CA contributes to K-ras initiated
transformation in vivo. Generation of ‘‘bigenic’’ mouse expressing
both activated PIK3CA and mutant Ras specifically in murine OSE
using MISIIR promoter is still a technical challenge. Because
mutant Ras is able to fully transform epithelium in vivo [42],
MISIIR-driven mutant Ras will induce very rapidly reproductive
system carcinoma in both female and male animals, and these
transgenic mice will lose reproductive ability. Therefore, it will be
difficult to generate ‘‘bigenic’’ animals by crossing MISIIR-driven
mutant Ras and MISIIR-driven myr-PIK3CA mice. We believe that
a novel transgenic strategy based on the Cre-loxp conditional
expression and intrabursal administration of adenovirus [6,8,9]
may allow us to further test PIK3CA and Ras cooperation in vivo in
the future.
Discussion
In agreement with our findings, several groups have demon-
strated that activation of PI3-kinase plays a crucial role in
epithelial cell transformation. For example, in human mammary
epithelial cells (HMECs), activation of the PI3-kinase pathway in
the presence of increased expression of c-myc, can functional
replace small T antigen and result in anchorage-independent
Figure 7. Overexpression of activated PIK3CA in OSE resulted in hyperplasia but not tumor formation. A. The ovarian surface epithelium
in wild type mouse. B. The ovarian surface epithelium in PIK3CA-Tg mouse. The epithelium origin was confirmed by cytokeratin staining.
doi:10.1371/journal.pone.0004295.g007
PIK3CA in OSE Transformation
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the PI3-kinase downstream mediator, Akt, in cooperation with
mutant K-ras, induces the OSE cell transformation [5]. Moreover,
two independent laboratories have recently reported that condi-
tional Pten deletion combined with mutant K-ras [8] or deregulated
Wnt/Catenin pathway [9] is able to induce endometrioid ovarian
tumors in mice in vivo. In all of these studies, only activation of wild
type PIK3CA alone seems insufficient to initiate epithelial
transformation, consistent with the results of our study. Although
mutant PIK3CA has been reported to be sufficient to transform
normal cells both in vitro [44,45,46] and in vivo [46,47], PIK3CA
mutation exhibits a relatively low frequency in ovarian cancer
(4.8–12%) [28,29,30,32] as compared to other cancer types. In
addition, PIK3CA mutation is rare in borderline [30] or early-stage
ovarian tumors (our unpublished observation). Therefore, PIK3CA
mutation might not be commonly involved in the transformation
of the OSE. However, PIK3CA amplification is one of most
common genetic alterations in ovarian cancer (23.6–40%)
[23,26,27,31] and more importantly, an increase in copy number
at chromosomal locus 3q26-qter, which harbors the PIK3CA gene,
has been observed in 40% of early-stage ovarian cancers [26],
suggesting that PIK3CA amplification might be one of the critical
events in OSE transformation. In this study, we tested overex-
pression of activated wild type PIK3CA in OSE in vivo and in vitro,
since it might more closely resemble natural OSE transformation
during human ovarian cancer development. Taken together, we
conclude that PIK3CA activation is one of the early molecular
events during OSE transformation, and activation of PIK3CA
contributes to tumorigenesis in certain cellular and molecular
contexts. However, PIK3CA activation might not be the initial
event in OSE transformation, and may require cooperation with
other oncogenic events such as K-ras mutation to maintain
transformed OSE growth.
Materials and Methods
Patients and Specimens
The specimens used in this study were collected at the
University of Pennsylvania and the University of Turin, Italy.
All tumors were from primary sites, and were immediately snap-
frozen and stored at 280uC. Ethical approval for this work was
granted by institution’s Institutional Review Boards (IRBs) of the
University of Pennsylvania and the University of Turin. Tissues
were obtained after informed written consent from patients
involved under a general tissue collection protocol approved by
the IRBs.
Cell lines and Cell Culture
A total of 15 ovarian cell lines were used in this study. All cancer
cell lines were cultured in DMEM medium (Invitrogen, Carlsbad,
CA) supplemented with 10% fetal bovine serum (FBS, Invitrogen).
Six independent immortalized human ovarian surface epithelial
cells (IOSEs, generously provided by Drs. Auersperg and Birrer)
were cultured in 1:1 media 199: MCDB 105 (Sigma, St. Louis,
MO) supplemented with 15% FBS. Murine ovarian surface
epithelial cells (MOSEs) were isolated and cultured as previously
reported [40].
Plasmid Construction
pMISIIRprom-TOPO, which contains the murine Mu ¨llerian
inhibitory substance type II receptor (MISIIR) gene 59 regulatory
region, was constructed by PCR amplification from mouse
genomic DNA [39]. pUSEamp-myr-mPIK3CA, which contains
murine PIK3CA under the control of CMV promoter, was ordered
from UPSTATE (UPSTATE, Lake Placid, NY). The activating
mutation was generated by addition of the avian src myristoylation
sequence (MGSSKSKPK) at the N-terminus. pCI-neo, which
contains a chimeric intron, was ordered from Promega (Promega,
Madison, WI). pMigR, which contains an internal ribosome entry
site (IRES) and downstream enhanced green fluorescent protein
(eGFP), was generously provided by Dr. Pear. We tagged myr-
PIK3CA in pUSEamp with eGFP, preceded by an IRES. The
IRES and eGFP were derived from pMigR. The XhoI-SalI-blunted
fragment containing the IRES and eGFP from plasmid pMigR
was inserted into the XhoI-ApaI-blunted plasmid pUSEamp-myr-
PIK3CA to construct plasmid pUSEamp-myr-PIK3CA-IRES-GFP.
The SacI-XhoI linearized fragment containing the chimeric intron
Figure 8. PIK3CA contributed to K-ras initiated transformation in vitro. A and B. Summary of colony numbers of the different combination of
oncogenes in soft agar assay.
doi:10.1371/journal.pone.0004295.g008
PIK3CA in OSE Transformation
PLoS ONE | www.plosone.org 6 January 2009 | Volume 4 | Issue 1 | e4295from plasmid PCI-neo was inserted into the EcoRV-XhoI linearized
plasmid pMISIIRprom-TOPO to construct plasmid pMISIIR-
prom-Intron. The MluI-ScaI linearized fragment containing the
MISIIR promoter and the intron from plasmid pMISIIRprom-
Intron was swapped into plasmid pUSEamp-myr-PIK3CA-IRES-
GFP to make plasmid pMISIIRprom-Intron-myr-PIK3CA-IRES-
GFP, in which the CMV promoter has been replaced by the
MISIIR promoter and the intron upstream of the PIK3CA ORF, as
well as the IRES, eGFP reporter and hGH polyA downstream (for
the detailed information for construction also see Figure S1). This
construct was used to generate a transgenic mouse expressing myr-
PIK3CA in the OSE.
Protein Isolation and Western blot
Cultured cells were lysed in 200 ml of lysis buffer containing
50 mM Tris-HCl (pH 7.4), 150 mM NaCl, and 1% Triton X-100.
Protein was separated by 10% SDS-PAGE under denaturing
conditions and transferred to nitrocellulose membrane. Mem-
branes were incubated with an anti-total AKT or anti-pAKT
antibodies (1:1,000, Cell Signaling Technology, Danvers, MA),
followed by incubation in anti-rabbit secondary antibody conju-
gated with horseradish peroxidase (1:10,000; Cell Signaling
Technology). Immunoreactive proteins were visualized using
enhanced chemiluminescence detection system (Amersham Bio-
sciences, Piscataway, NJ).
Transgenic Mice
The animal study protocol was reviewed and approved by the
institutional animal care and use committee (IACUC) of the
University of Pennsylvania. Transgenic mice were generated by
the University of Pennsylvania’s Transgenic & Chimeric Mouse
Facility. The linearized transgene DNA fragment (MISIIR-myr-
PIK3CA-IRES-GFP) was injected by microinjection into pronuclei
of day-0.5 embryos of the first generation of a hybrid genetic
background of C57BL/6 and C3H (B6C3F1) mice. Injected
embryos were implanted into the oviducts of day-0.5 pseudo
pregnant female Swiss Webster mice.
Genotyping
Tails from the resulting pups were clipped 3 weeks after birth
for genotype analysis. Genomic DNA was isolated by the DNeasy
Tissue kit (QIAGEN, Valencia, CA). Presence of the transgene
was confirmed by PCR amplification of a 486-bp fragment (Frag1)
of the intron-myr-PIK3CA as well as a 324–bp fragment (Frag2) of
the eGFP. Specific primers for eGFP were as follows: Frag1
forward primer: 59-AGG CAC TGG GCA GGT AAG TAT,
Frag1 reverse primer: 59-CAT GTT TGA TGG TGA CGA
GTG; Frag2 forward primer: 59-CGA CAA CCA CTA CCT
GAG CA, Frag2 reverse primer: 59-TTA GGA AAG GAC AGT
GGG AGT G. Genomic DNA (2 ml) was amplified in 25 ml of the
PCR reaction containing 200 mmol/L each dNTP, 20 pmol of
each primer, the standard buffer supplemented with 1.5 U Taq
polymerase (Roche, Indianapolis, IN), and 1.5 mmol/L MgCl2.
After initial denaturation at 94uC for 4 minutes, 30 cycles of PCR
were performed with denaturation at 94uC for 15 seconds,
annealing at 55uC for 20 seconds, and extension at 72uC for
45 seconds. The last extension was at 72uC for 7 minutes.
RNA Isolation and Reverse Transcriptase-Polymerase
Chain Reaction (RT-PCR)
Total RNA was isolated from 100 to 500 mg of fresh tissue or
1610
6 cultured cells with TRIzol reagent (Invitrogen). Total RNA
was reverse-transcribed using the Superscript first-strand synthesis
kit for RT-PCR (Invitrogen). Reverse-transcribed cDNA was
amplified in 25 ml of the PCR reaction containing 200 mmol/L
each dNTP, 20 pmol of each primer, the standard buffer
supplemented with 1.5 U Taq polymerase (Roche), and
1.5 mmol/L MgCl2. After initial denaturation at 94uC for
4 minutes, 35 cycles of PCR were performed with denaturation at
94uC for 15 seconds, annealing at 55uC for 20 seconds, and
extensionat72uCfor45 seconds.Thelastextensionwasat72uCfor
7 minutes. Specific primers for GFP were as follows: eGFP forward
primer:59-AGCTGACCCTGAAGTTCATCTG,GFPreverse
primer: 59-GAT CTT GAA GTT CAC CTT GAT GC.
Real-time RT-PCR
cDNA was quantified by real-time RT-PCR on the ABI Prism
7900 Sequence Detection System (Applied Biosystems, Foster
City, CA). PCR was performed using Sybr Green PCR Core
reagents (Applied Biosystems). PCR amplification of the house-
keeping genes GAPDH was performed for each sample as a
control for sample loading and to allow normalization among
samples. A standard curve was constructed containing the PIK3CA
cDNA and amplified by the real-time PCR. Each sample was run
in duplicate and each PCR experiment included two non-template
control wells.
Laser capture microdissection (LCM)
LCM was performed as described by our previous study [48].
Briefly, cryosections (10 mm) from human or mouse ovaries were
mounted on a polyethylene foil slide (SLMicrotest, Jena,Germany).
After rapid hematoxylin staining, sections were subjected to LCM
utilizing the mCUT Laser-MicroBeam System (SL Microtest) with a
fine ultraviolet laser, which enables the contact-free isolation of
single cells or groups of cells. The microdissected cells were
catapulted into the lid of a 0.5-ml reaction tube containing RNA
isolation buffer. RNA was isolated by TRIzol reagent.
Immunostaining
Immunohistochemical staining was performed using the avidin-
biotin-peroxidase method [49]. Sections were pretreated with
0.03% H2O2 for 20 minutes to block endogenous peroxidase
activity and incubated in matched normal sera (Vector Laborato-
ries, Burlingame, CA). The following primary antibodies were used
in this study: Cytokeratin (Hybridoma Bank, Iowa City, IA, 1:200)
rabbit anti-p110a (Cell Signaling, Danvers, MA 1:200) and mouse
anti-human p110a (Pharmigen, CA, 1:200). Mouse on Mouse
(M.O.M.) kit (Vector) was used for monoclonal antibody. The
Vectastain ABC kit was applied as described by the manufacturer
(Vector Laboratories). Sections were counterstained with Gill’s
hematoxylin(VectorLaboratories).Imageswereacquiredthrougha
Cool SNAP Pro color digital camera (Media Cybernetics).
RNA interference/Transfection of Synthetic siRNA
Synthetic SMARTpool siRNAs targeting mouse PIK3CA (Dhar-
macon, Chicago, IL) or appropriate siCONTROL non-targeting
siRNAs (Dharmacon) were transfected into cultured cells.
Transfection was performed using Lipofectamine
TM2000 (Invitro-
gen) following the manufacturer’s instructions. Forty-eight hrs post
transfection, total RNA was extracted to examine the PIK3CA
expression by real-time RT-PCR.
In vitro Cell Transformation Assay
A soft agar assay was performed using Cell Transformation
Detection Assay Kit (Chemicon, Temecula, CA) following the
manufacturer’s instructions [41].
PIK3CA in OSE Transformation
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Statistical analysis was performed using the SPSS statistics
software package (SPSS, Chicago, IL). All results were expressed
as mean6SD, and p,0.05 was used for significance.
Supporting Information
Figure S1
Found at: doi:10.1371/journal.pone.0004295.s001 (0.05 MB
PDF)
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